A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 13, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the UTHR SEC filings page.
United Therapeutics Corp (UTHR) reported $3.2B in revenue over the twelve months to Sep 30, 2026, up 1.9% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
United Therapeutics remains highly cash-generative and lightly leveraged, while 2025 capital spending consumed more of that cash.
Operating cash flow rose17.6% while free cash flow fell3.7% in FY2025, showing that accounting earnings continued converting into cash even as less remained after reinvestment. Capital expenditures increased111.2% to$520M , making expansion the main reason cash conversion weakened rather than a deterioration in operating receipts.
Liabilities fell
Revenue grew
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of United Therapeutics Corp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. United Therapeutics Corp scores 92/100 on it among other operating companies.
Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. United Therapeutics Corp scores 78/100 on it among other operating companies.
United Therapeutics Corp carried $0.11 of total liabilities for every $1 of shareholders' equity at the end of fiscal year 2025. With no long-term debt figure for fiscal year 2025, United Therapeutics Corp is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 81/100 among other operating companies.
United Therapeutics Corp held $6.60 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 6.60. Liquidity ranks operating companies on that ratio, and United Therapeutics Corp scores 95/100 among other operating companies.
Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. United Therapeutics Corp scores 96/100 on it among other operating companies.
Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. United Therapeutics Corp scores 87/100 on it among other operating companies.
United Therapeutics Corp scores 22.30, well above the 2.99 safe threshold. The largest contribution to the score comes from a market capitalization of $25.2B against total liabilities of $783.8M. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
United Therapeutics Corp passes 7 of 8 computable financial strength tests (1 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), all 2 leverage/liquidity signals pass, 1 of 2 operating efficiency signals passes.
For every $1 of reported earnings, United Therapeutics Corp generates $1.17 in operating cash flow ($1.6B OCF vs $1.3B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
United Therapeutics Corp earns $76.54 in operating income for every $1 of interest expense ($1.5B vs $19.5M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
United Therapeutics Corp generated $832.5M in revenue in Q3 2026. This represents an increase of 4.1% from the same quarter a year earlier. Against the prior quarter it is up 6.3%.
United Therapeutics Corp's EBITDA was $334.2M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.6% from the same quarter a year earlier. Against the prior quarter it is down 5.9%.
United Therapeutics Corp reported $258.6M in net income in Q3 2026. This represents a decrease of 23.6% from the same quarter a year earlier. Against the prior quarter it is down 22.3%.
United Therapeutics Corp earned $5.71 per diluted share (EPS) in Q3 2026. This represents a decrease of 20.3% from the same quarter a year earlier. Against the prior quarter it is down 21.5%.
Cash & Balance Sheet
United Therapeutics Corp generated $125.8M in free cash flow in Q3 2026, representing cash available after capex. This represents a decrease of 64.2% from the same quarter a year earlier. Against the prior quarter it is down 38.8%.
United Therapeutics Corp held $1.2B in cash as of Q3 2026; no long-term debt figure is on record for that period.
Not reported for Q3 2026.
Margins & Returns
United Therapeutics Corp's gross margin was 88.1% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is up 0.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.8 percentage points.
United Therapeutics Corp's operating margin was 37.0% in Q3 2026, reflecting core business profitability. This is down 11.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 5.3 percentage points.
United Therapeutics Corp's net profit margin was 31.1% in Q3 2026, showing the share of revenue converted to profit. This is down 11.3 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.4 percentage points.
United Therapeutics Corp's quarterly ROE was 4.1% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is down 1.0 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.1 percentage points.
Capital Allocation
United Therapeutics Corp invested $279.2M in research and development in Q3 2026. This represents an increase of 119.0% from the same quarter a year earlier. Against the prior quarter it is up 90.8%.
United Therapeutics Corp spent $500.0M on share buybacks in Q3 2026, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 50.0% from the same quarter a year earlier. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
United Therapeutics Corp invested $180.7M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 14.2% from the same quarter a year earlier. Against the prior quarter it is up 67.3%.
UTHR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Revenue | $832.5M+4.1% | $783.3M-1.9% | $781.5M-1.6% | $790.2M+7.4% | $799.5M+6.8% | $798.6M+11.7% | $794.4M+17.2% | $735.9M+19.7% |
| Cost of Revenue | $99.1M-1.8% | $99.5M+13.6% | $133.4M+44.2% | $103.4M+36.2% | $100.9M+21.4% | $87.6M+12.6% | $92.5M+26.9% | $75.9M+6.9% |
| Gross Profit | $733.4M+5.0% | $683.8M-3.8% | $648.1M-7.7% | $686.8M+4.1% | $698.6M+4.9% | $711.0M+11.6% | $701.9M+16.1% | $660.0M+21.4% |
| R&D Expenses | $279.2M+119.0% | $146.3M+9.2% | $138.2M-7.2% | $139.5M+4.3% | $127.5M+23.2% | $134.0M-4.0% | $149.0M+43.1% | $133.8M-11.6% |
| SG&A Expenses | $146.4M-19.8% | $206.7M-2.7% | $184.1M+8.2% | $190.6M+13.1% | $182.6M-16.7% | $212.5M+19.7% | $170.1M+17.8% | $168.5M+27.5% |
| Operating Income | $307.8M-20.8% | $330.8M-9.2% | $325.8M-14.9% | $356.7M-0.3% | $388.5M+13.2% | $364.5M+13.9% | $382.8M+7.4% | $357.7M+37.5% |
| EBITDA | $334.2M-18.6% | $355.0M-7.9% | $348.4M-13.5% | $379.5M+0.6% | $410.4M+13.3% | $385.6M+13.9% | $402.6M+8.4% | $377.4M+37.8% |
| Interest Expense | $2.9M-3.3% | $2.9M-60.3% | $3.0M-50.8% | $3.1M-60.8% | $3.0M-70.3% | $7.3M-37.1% | $6.1M-54.1% | $7.9M-47.7% |
| Income Tax | $114.2M+15.0% | $39.7M-59.9% | $43.4M-57.2% | $79.7M-16.3% | $99.3M+24.9% | $98.9M+28.1% | $101.3M+10.1% | $95.2M+21.6% |
| Net Income | $258.6M-23.6% | $333.0M+7.6% | $274.9M-14.7% | $364.3M+20.9% | $338.7M+9.6% | $309.5M+11.3% | $322.2M+5.1% | $301.3M+38.8% |
| EPS (Basic) | $6.06-21.6% | $7.82+14.0% | $6.32-12.0% | $8.37+24.7% | $7.73+11.5% | $6.86+9.6% | $7.18+10.1% | $6.71+45.9% |
| EPS (Diluted) | $5.71-20.3% | $7.27+13.4% | $5.82-12.2% | $7.69+23.8% | $7.16+12.1% | $6.41+9.6% | $6.63+7.5% | $6.21+43.4% |
| Diluted Shares (Avg) | 45M-4.2% | 46M-5.2% | 47M-2.9% | N/A | 47M-2.3% | 48M+1.7% | 49M-2.2% | N/A |
UTHR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7.0B-4.3% | $7.2B-8.7% | $6.7B-13.3% | $7.9B+7.0% | $7.4B+3.2% | $7.9B+17.6% | $7.7B+19.2% | $7.4B+2.7% |
| Current Assets | $2.9B-17.6% | $3.5B-9.0% | $2.9B-27.1% | $3.7B-4.4% | $3.5B-12.7% | $3.8B+5.7% | $3.9B+21.3% | $3.9B+9.1% |
| Cash & Equivalents | $1.2B-11.3% | $1.8B+13.2% | $1.3B-32.6% | $1.6B-8.3% | $1.3B-13.8% | $1.6B+17.5% | $1.9B+51.8% | $1.7B+40.5% |
| Short-Term Investments | $879.0M-38.4% | $859.1M-41.0% | $874.0M-38.5% | $1.4B-13.2% | $1.4B-19.5% | $1.5B-9.9% | $1.4B-2.4% | $1.6B-12.1% |
| Inventory | $201.9M+14.4% | $193.8M+14.5% | $178.3M+7.8% | $183.1M+16.0% | $176.5M+20.3% | $169.2M+24.0% | $165.4M+37.6% | $157.9M+41.2% |
| Accounts Receivable | $348.6M+17.1% | $310.3M-18.2% | $312.0M-3.1% | $350.2M+25.4% | $297.7M-12.9% | $379.3M+30.5% | $322.0M+4.8% | $279.3M+0.1% |
| Long-Term Investments | $1.5B-6.3% | $1.1B-40.5% | $1.3B-23.0% | $1.8B+20.4% | $1.6B+22.5% | $1.9B+44.1% | $1.7B+14.7% | $1.5B-22.8% |
| Goodwill | N/A | N/A | N/A | $32.3M0.0% | N/A | N/A | N/A | $32.3M-4.2% |
| Total Liabilities | $758.1M-0.4% | $819.8M+11.6% | $813.1M-13.2% | $783.8M-14.8% | $760.9M-25.6% | $734.4M-28.4% | $936.7M-19.0% | $920.0M-22.2% |
| Current Liabilities | $624.3M+14.3% | $607.8M+15.3% | $599.1M-17.0% | $560.6M-24.0% | $546.3M-37.5% | $527.1M-36.7% | $721.5M-16.2% | $738.1M-8.2% |
| Non-Current Liabilities | $133.8M-37.7% | $212.0M+2.3% | $214.0M-0.6% | $223.2M+22.7% | $214.6M+44.2% | $207.3M+7.0% | $215.2M-27.4% | $181.9M-51.9% |
| Total Equity | $6.3B-4.8% | $6.4B-10.8% | $5.9B-13.3% | $7.1B+10.1% | $6.6B+8.0% | $7.2B+25.9% | $6.8B+27.5% | $6.4B+7.7% |
| Retained Earnings | $9.4B+15.0% | $9.2B+16.7% | $8.8B+17.1% | $8.6B+18.5% | $8.2B+18.4% | $7.9B+18.8% | $7.5B+19.1% | $7.2B+19.8% |
Not reported in any period shown, so not listed: Long-Term Debt.
UTHR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $306.5M-45.5% | $313.6M+63.6% | $463.3M+0.5% | $346.2M+1.5% | $562.1M+49.0% | $191.7M-17.4% | $461.2M+22.5% | $341.2M+126.4% |
| Depreciation & Amortization | $26.4M+20.5% | $24.2M+14.7% | $22.6M+14.1% | $22.8M+15.7% | $21.9M+14.7% | $21.1M+12.8% | $19.8M+32.0% | $19.7M+43.8% |
| Stock-Based Compensation | $41.0M+4.9% | $43.4M+14.8% | $33.9M+6.6% | N/A | $39.1M-6.2% | $37.8M-23.9% | $31.8M+24.2% | N/A |
| Capital Expenditures | $180.7M-14.2% | $108.0M+73.6% | $100.8M+34.6% | $172.9M+99.4% | $210.5M+175.2% | $62.2M+37.9% | $74.9M+96.1% | $86.7M+10.2% |
| Free Cash Flow | $125.8M-64.2% | $205.6M+58.8% | $362.5M-6.2% | $173.3M-31.9% | $351.6M+16.9% | $129.5M-30.8% | $386.3M+14.2% | $254.5M+253.5% |
| Investing Cash Flow | -$510.6M-462.4% | $87.5Mn/m | $743.7Mn/m | -$227.6Mn/m | $140.9Mn/m | -$299.9Mn/m | -$164.7M-122.4% | -$123.2M-392.6% |
| Financing Cash Flow | -$410.2Mn/m | $122.4Mn/m | -$1.5Bn/m | $98.4Mn/m | -$956.0Mn/m | -$198.6Mn/m | -$93.8Mn/m | -$74.7Mn/m |
| Share Buybacks | $500.0M-50.0% | $0n/m | $1.5Bn/m | $0n/m | $1.0Bn/m | $0n/m | $0-100.0% | $0n/m |
Not reported in any period shown, so not listed: Dividends Paid.
UTHR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 88.1%+0.7pp | 87.3%-1.7pp | 82.9%-5.4pp | 86.9%-2.8pp | 87.4%-1.5pp | 89.0%-0.1pp | 88.4%-0.9pp | 89.7%+1.2pp |
| Operating Margin | 37.0%-11.6pp | 42.2%-3.4pp | 41.7%-6.5pp | 45.1%-3.5pp | 48.6%+2.8pp | 45.6%+0.9pp | 48.2%-4.4pp | 48.6%+6.3pp |
| Net Margin | 31.1%-11.3pp | 42.5%+3.7pp | 35.2%-5.4pp | 46.1%+5.2pp | 42.4%+1.1pp | 38.8%-0.1pp | 40.6%-4.7pp | 40.9%+5.6pp |
| Return on Equity | 4.1%-1.0pp | 5.2%+0.9pp | 4.7%-0.1pp | 5.1%+0.4pp | 5.1%+0.1pp | 4.3%-0.6pp | 4.7%-1.0pp | 4.7%+1.1pp |
| Return on Assets | 3.7%-0.9pp | 4.6%+0.7pp | 4.1%-0.1pp | 4.6%+0.5pp | 4.6%+0.3pp | 3.9%-0.2pp | 4.2%-0.6pp | 4.1%+1.1pp |
| Current Ratio | 4.61-1.8x | 5.73-1.5x | 4.79-0.7x | 6.60+1.4x | 6.40+1.8x | 7.26+2.9x | 5.46+1.7x | 5.25+0.8x |
| Liabilities-to-Equity | 0.120.0x | 0.130.0x | 0.140.0x | 0.110.0x | 0.12-0.1x | 0.10-0.1x | 0.14-0.1x | 0.14-0.1x |
| Asset Turnover | 0.120.0x | 0.110.0x | 0.120.0x | 0.100.0x | 0.110.0x | 0.100.0x | 0.100.0x | 0.100.0x |
| FCF Margin | 15.1%-28.9pp | 26.3%+10.0pp | 46.4%-2.2pp | 21.9%-12.7pp | 44.0%+3.8pp | 16.2%-9.9pp | 48.6%-1.3pp | 34.6%+22.9pp |
Not reported in any period shown, so not listed: Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| United Therapeutics Corp UTHR | FY2025 | $3.2B | $1.3B | 41.9% | $25.2B | 88/100 |
| Viatris Inc. VTRS | FY2025 | $14.3B | -$3.5B | -24.6% | $23.9B | 28/100 |
| Neurocrine Biosciences Inc NBIX | FY2025 | $2.9B | $478.6M | 16.7% | $16.9B | 79/100 |
| Zoetis Inc. ZTS | FY2025 | $9.5B | $2.7B | 28.2% | $34.1B | 72/100 |
| Teva Pharmaceutical Industries Limited TEVA | FY2025 | $17.3B | $1.4B | 8.2% | $51.9B | 34/100 |
| Haleon plc HLN | FY2025 | $14.8B | $2.2B | 15.1% | $40.2B | 57/100 |
Where United Therapeutics Corp Ranks
Frequently Asked Questions
United Therapeutics Corp (UTHR) reported $3.2B in total revenue for fiscal year 2025. This represents a 10.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
United Therapeutics Corp (UTHR) revenue grew by 10.6% year-over-year, from $2.9B to $3.2B in fiscal year 2025.
Yes, United Therapeutics Corp (UTHR) reported a net income of $1.2B over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net income of $1.3B, with a net profit margin of 41.9%.
United Therapeutics Corp (UTHR) had EBITDA of $1.6B in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
United Therapeutics Corp (UTHR) had a gross margin of 87.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
United Therapeutics Corp (UTHR) had an operating margin of 46.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
United Therapeutics Corp (UTHR) had a net profit margin of 41.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
United Therapeutics Corp (UTHR) has a return on equity of 18.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
United Therapeutics Corp (UTHR) generated $1.0B in free cash flow during fiscal year 2025. This represents a -3.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
United Therapeutics Corp (UTHR) generated $1.6B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
United Therapeutics Corp (UTHR) had $7.9B in total assets as of fiscal year 2025, including both current and long-term assets.
United Therapeutics Corp (UTHR) invested $520.5M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
United Therapeutics Corp (UTHR) invested $550.0M in research and development during fiscal year 2025.
United Therapeutics Corp (UTHR) had a current ratio of 6.60 as of fiscal year 2025, which is generally considered healthy.
United Therapeutics Corp (UTHR) had a liabilities-to-equity ratio of 0.11 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
United Therapeutics Corp (UTHR) had a return on assets of 16.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
United Therapeutics Corp (UTHR) trades at 20.5x earnings, its market capitalization divided by $1.2B net income, trailing 12 months to September 30, 2026. The market capitalization is $25.2B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
United Therapeutics Corp (UTHR) trades at 7.9x sales, its market capitalization divided by $3.2B revenue, trailing 12 months to September 30, 2026. The market capitalization is $25.2B as of Nov 13, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
United Therapeutics Corp (UTHR) has an Altman Z-Score of 22.30, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
United Therapeutics Corp (UTHR) has a Piotroski F-Score of 7 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
United Therapeutics Corp (UTHR) has an earnings quality ratio of 1.17x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
United Therapeutics Corp (UTHR) has an interest coverage ratio of 76.54x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
United Therapeutics Corp (UTHR) scores 88 out of 100 on our Financial Health Score, indicating strong standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.